Form 4: Verastem Director Michael Kauffman Receives Stock Options and Restricted Stock Units

Director Michael Kauffman of Verastem, Inc. was granted stock options and restricted stock units (RSUs) on June 18, 2024, according to a recent SEC Form 4 filing.

Summary

• On June 18, 2024, Michael Kauffman, a director of Verastem, Inc., received 8,333 restricted stock units (RSUs) and options to purchase 12,500 shares of common stock.
• The RSUs vest in twelve equal monthly installments starting in June 2024 and ending in April 2025, with the final installment vesting no later than May 31, 2025, contingent upon continued service as a director.
• The stock options, with an exercise price of $3.27, also vest in twelve equal monthly installments over the same period, subject to the same condition of continued service.
• Following these transactions, Kauffman directly owns 8,883 shares of Verastem common stock and options to purchase 12,500 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of equity-based compensation is a standard practice and generally viewed favorably as it aligns management's interests with those of shareholders.

Positives

• The grant of RSUs and stock options aligns the director's interests with those of the shareholders, incentivizing continued service and performance.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

Stock option and RSU grants are common forms of executive compensation in the biotechnology industry, aligning management's interests with shareholder value and incentivizing long-term performance.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded biotechnology companies.
• The vesting schedule of the RSUs and stock options is typical, with monthly or quarterly vesting over a one-to-three-year period being common.
• Comparable companies such as Kura Oncology or Sierra Oncology also utilize stock options and RSU grants as part of their director compensation packages.

Stakeholder Impact

• Shareholders may view the grant of RSUs and stock options positively as it incentivizes the director to work towards increasing shareholder value.
• The director benefits from the potential future value of the RSUs and stock options.

Key Dates